Nexalin Technology, Inc. income statement

In fiscal 2025, Nexalin Technology, Inc. reported revenue of $301,647, up 78.8% on the year before, operating income of −$8.4m (a -2781.7% margin) and net income of −$8.2m, or −$0.50 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Nexalin Technology, Inc.: income statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	144	1,321	111	169	302	217
Cost of revenue	21	363	26	37	61	30
Gross profit	123	958	85	132	240	187
Research and development	139	511	1,922	1,191	1,084	1,362
Selling, general and administrative	5,215	1,492	1,897	4,229	4,398	4,151
Operating income	−6,019	−1,833	−5,696	−7,755	−8,391	−9,126
Interest expense	82	59	39	−3	−8	−3
Net interest income	—	—	39	−3	−8	−3
Income before tax	—	—	−4,649	−7,612	−8,221	−8,989
Net income	−6,078	−1,698	−4,649	−7,607	−8,222	−8,989
Diluted EPS	—	−$0.30	−$0.63	−$0.83	−$0.50	−$0.46
Diluted shares (average)	—	6m	7m	9m	16m	19m
EBITDA	−6,018	−1,832	−5,696	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Nexalin Technology, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	36	27	41	71	18	172	15	12
Cost of revenue	13	7	14	23	4	21	2	3
Gross profit	23	20	27	48	14	151	13	9
Research and development	179	737	406	226	227	225	346	564
Selling, general and administrative	1,797	1,350	929	894	1,420	1,155	793	783
Operating income	−2,509	−2,875	−2,011	−1,621	−2,346	−2,413	−2,120	−2,247
Interest expense	−1	−2	−1	−5	−2	−0	−0	−0
Net interest income	−1	−2	−1	−5	−2	−0	−0	−0
Income before tax	−2,448	−2,833	−1,987	−1,581	−2,276	−2,377	−2,097	−2,239
Net income	−2,448	−2,833	−1,988	−1,581	−2,276	−2,377	−2,097	−2,239
Diluted EPS	−$0.23	−$0.28	−$0.15	−$0.10	−$0.13	−$0.13	−$0.11	−$0.11
EBITDA	—	—	—	—	—	—	−2,116	−2,245

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NXL vs QTEX NXL vs PAVM NXL vs POAS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Nexalin Technology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nexalin Technology, Inc.